Fatty liver disease affects millions of people worldwide, with nonalcoholic fatty liver disease (NAFLD) being the most common ...

A new study reveals the shocking relationship between early-onset colorectal cancer and a super common disease that impacts ...

This article will briefly discuss prevalence studies and the pathophysiology of NAFLD and focus on current discussions related to the specific lesions in the pathology of NASH, including the ...

Metabolic dysfunction-associated fatty liver disease is now recognised as the most common chronic liver disease globally, ...

Nonalcoholic steatohepatitis (NASH) is a type of nonalcoholic fatty liver disease (NAFLD). It involves a buildup of fat in your liver, inflammation, and damage. Nonalcoholic steatohepatitis (NASH ...

To test their new drug, the researchers conducted experiments on mice that were fed a high-fat diet, which typically leads to ...

A doctor has shared the warning signs of fatty liver disease you might not initially realise are a sign of a bigger issue. Dr ...

Madrigal Pharmaceuticals beat Q1 sales estimates with Rezdiffra, and catalysts like EU approval and pipeline plans add upside ...

At the moment, Madrigal Pharmaceuticals seems to be in the lead to bring a NASH drug to market, after its daily oral drug resmetirom met primary and secondary objectives in a phase 3 NAFLD trial ...

Nonalcoholic fatty liver disease (NAFLD ... steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). MASH is when the extra fat in the liver starts to cause damage.

The diabetes and weight loss drug semaglutide reversed liver scarring and inflammation. It’s among several drugs in the works for the condition MASH.

Discover a study which explores the impact of MASLD on pregnancy, from preconception to postpartum. Learn more.